TrialLancet (London, England)2019

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Helena M Earl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.